This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

The CREATE-ECLA Randomized Controlled Trial

The CREATE-ECLA Trial Group Investigators*

JAMA. 2005;293:437-446.

Context  Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI.

Objective  To determine the effect of high-dose GIK infusion on mortality in patients with STEMI.

Design, Setting, and Participants  Randomized controlled trial conducted in 470 centers worldwide among 20 201 patients with STEMI who presented within 12 hours of symptom onset. The mean age of patients was 58.6 years, and evidence-based therapies were commonly used.

Intervention  Patients were randomly assigned to receive GIK intravenous infusion for 24 hours plus usual care (n = 10 091) or to receive usual care alone (controls; n = 10 110).

Main Outcome Measures  Mortality, cardiac arrest, cardiogenic shock, and reinfarction at 30 days after randomization.

Results  At 30 days, 976 control patients (9.7%) and 1004 GIK infusion patients (10.0%) died (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.95-1.13; P = .45). There were no significant differences in the rates of cardiac arrest (1.5% [151/10 107] in control and 1.4% [139/10 088] in GIK infusion; HR, 0.93; 95% CI, 0.74-1.17; P = .51), cardiogenic shock (6.3% [640/10 107] vs 6.6% [667/10 088]; HR, 1.05; 95% CI, 0.94-1.17; P = .38), or reinfarction (2.4% [246/10 107] vs 2.3% [236/10 088]; HR, 0.98; 95% CI, 0.82-1.17; P = .81). The rates of heart failure at 7 days after randomization were also similar between the groups (16.9% [1711/10 107] vs 17.1% [1721/10 088]; HR, 1.01; 95% CI, 0.95-1.08; P = .72). The lack of benefit of GIK infusion on mortality was consistent in prespecified subgroups, including in those with and without diabetes, in those presenting with and without heart failure, in those presenting early and later after symptom onset, and in those receiving and not receiving reperfusion therapy (thrombolysis or primary percutaneous coronary intervention).

Conclusion  In this large, international randomized trial, high-dose GIK infusion had a neutral effect on mortality, cardiac arrest, and cardiogenic shock in patients with acute STEMI.

*Authors/Writing Committee: Shamir R. Mehta, MD, MSc, FRCPC, Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario; Salim Yusuf, MBBS, DPhil, Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences; Rafael Díaz, MD, Estudios Cardiologica Latin America, Rosario, Argentina; Jun Zhu, MD, Cardiovascular Institute and Fu Wai Hospital, Chinese Hypertension League Institute, Beijing, China; Prem Pais, MD, MSc, St John’s Medical College National Academy of Health Sciences, Bangalore, India; Denis Xavier, MD, St John’s Medical College National Academy of Health Sciences; Ernesto Paolasso, MD, Estudios Cardiologica Latin America; Rashid Ahmed, BScH, Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences; Changchun Xie, PhD, Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences; Khawar Kazmi, MD, Aga Khan University, Karachi, Pakistan; Javed Tai, MD, Aga Khan University; Andrés Orlandini, MD, Estudios Cardiologica Latin America; Janice Pogue, MSc, Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences; Lisheng Liu, MD, Cardiovascular Institute and Fu Wai Hospital, Chinese Hypertension League Institute.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Carl S. Apstein
JAMA. 2005;293(21):2596-2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Leonard A. Cobb, Thomas Killip, Costas T. Lambrew, Bruce A. MacLeod, Charles E. Rackley, Harry P. Selker, and Robert J. Zalenski
JAMA. 2005;293(21):2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Jayant Dey, Lawrence Blonde, Alan Burshell, Peggy Bolton, and Anita Richard
JAMA. 2005;293(21):2597-2598.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial—Reply
Shamir R. Mehta, Salim Yusuf, Rafael Diaz, and Ernesto Paolasso
JAMA. 2005;293(21):2598.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Harry P. Selker, Joanne Ingwall, and Charles E. Rackley
JAMA. 2008;299(20):2385.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Rohit R. Arora and Srikanth Katragadda
JAMA. 2008;299(20):2386.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI—Reply
Abhinav Goyal, Rafael Díaz, and Shamir R. Mehta
JAMA. 2008;299(20):2387-2388.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation
The CREATE Trial Group Investigators*
JAMA. 2005;293(4):427-435.
ABSTRACT | FULL TEXT  

Simple Principles of Clinical Trials Remain Powerful
Robert M. Califf
JAMA. 2005;293(4):489-491.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Critical Care Settings: A Systematic Review and Meta-Analysis
Puskarich et al.
J Clin Pharmacol 2009;49:758-767.
ABSTRACT | FULL TEXT  

Cardiovascular Disease, Neuropathy, and Retinopathy
Bloomgarden
Diabetes Care 2009;32:e64-e68.
FULL TEXT  

American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control
Moghissi et al.
Diabetes Care 2009;32:1119-1131.
FULL TEXT  

Hyperglycaemia in acute coronary syndromes: risk-marker or therapeutic target?
Anantharaman et al.
Heart 2009;95:697-703.
ABSTRACT | FULL TEXT  

Acute Myocardial Infarction, Hyperglycemia, and Insulin
Dandona et al.
J Am Coll Cardiol 2009;53:1437-1439.
FULL TEXT  

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Timmers et al.
J Am Coll Cardiol 2009;53:501-510.
ABSTRACT | FULL TEXT  

Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting.
Ceriello et al.
J Am Coll Cardiol 2009;53:S9-13.
ABSTRACT | FULL TEXT  

Insulin as an anti-inflammatory and antiatherogenic modulator.
Dandona et al.
J Am Coll Cardiol 2009;53:S14-S20.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2009
American Diabetes Association
Diabetes Care 2009;32:S13-S61.
FULL TEXT  

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:
Authors/Task Force Members et al.
Eur Heart J 2008;29:2909-2945.
FULL TEXT  

Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points
Goyal et al.
Diabetes and Vascular Disease Research 2008;5:276-284.
ABSTRACT  

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Wiviott et al.
Circulation 2008;118:1626-1636.
ABSTRACT | FULL TEXT  

Impact of anaerobic glycolysis and oxidative substrate selection on contractile function and mechanical efficiency during moderate severity ischemia
Zhou et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;295:H939-H945.
ABSTRACT | FULL TEXT  

Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions
Stone
Circulation 2008;118:552-566.
FULL TEXT  

Insulin signalling in the heart
Bertrand et al.
Cardiovasc Res 2008;79:238-248.
ABSTRACT | FULL TEXT  

The malonyl CoA axis as a potential target for treating ischaemic heart disease
Ussher and Lopaschuk
Cardiovasc Res 2008;79:259-268.
ABSTRACT | FULL TEXT  

Management of Hyperglycemia in Acute Stroke: How, When, and for Whom?
McCormick et al.
Stroke 2008;39:2177-2185.
FULL TEXT  

Role of glucose metabolism in the recovery of postischemic LV mechanical function: effects of insulin and other metabolic modulators
Gandhi et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H2576-H2586.
ABSTRACT | FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Selker et al.
JAMA 2008;299:2385-2385.
FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI
Arora and Katragadda
JAMA 2008;299:2386-2386.
FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With STEMI--Reply
Goyal et al.
JAMA 2008;299:2387-2388.
FULL TEXT  

Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection
Kloner and Nesto
Circulation 2008;117:2523-2533.
FULL TEXT  

Review: An examination of effect estimation in factorial and standardly-tailored designs
Allore and Murphy
Clin Trials 2008;5:121-130.
ABSTRACT  

Perioperative hyperinsulinaemic normoglycaemic clamp causes hypolipidaemia after coronary artery surgery
Zuurbier et al.
Br J Anaesth 2008;100:442-450.
ABSTRACT | FULL TEXT  

Hypolipidaemic effects of high-dose insulin therapy
Evans and Niu
Br J Anaesth 2008;100:429-433.
FULL TEXT  

Effect of Perioperative Insulin Infusion on Surgical Morbidity and Mortality: Systematic Review and Meta-analysis of Randomized Trials
Gandhi et al.
Mayo Clin Proc. 2008;83:418-430.
ABSTRACT | FULL TEXT  

Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism
Deedwania et al.
Circulation 2008;117:1610-1619.
ABSTRACT | FULL TEXT  

Glucose: A Biomarker in Acute Myocardial Infarction Ready for Prime Time?
Nesto and Lago
Circulation 2008;117:990-992.
FULL TEXT  

Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk
Kosiborod et al.
Circulation 2008;117:1018-1027.
ABSTRACT | FULL TEXT  

Insulin-induced myocardial protection in isolated ischemic rat hearts requires p38 MAPK phosphorylation of Hsp27
Li et al.
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H74-H87.
ABSTRACT | FULL TEXT  

Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury
Chai et al.
Am. J. Physiol. Endocrinol. Metab. 2008;294:E183-E189.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes--2008
American Diabetes Association
Diabetes Care 2008;31:S12-S54.
FULL TEXT  

Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR
Merritt et al.
Proc. Natl. Acad. Sci. USA 2007;104:19773-19777.
ABSTRACT | FULL TEXT  

Targeting Glucose in Acute Myocardial Infarction: Has glucose, insulin, and potassium infusion missed the target?
Chaudhuri et al.
Diabetes Care 2007;30:3026-3028.
FULL TEXT  

Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Diaz et al.
JAMA 2007;298:2399-2405.
ABSTRACT | FULL TEXT  

Myocardial Reperfusion Injury
Yellon and Hausenloy
NEJM 2007;357:1121-1135.
FULL TEXT  

Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK
Parikh et al.
Diabetes and Vascular Disease Research 2007;4:222-225.
ABSTRACT  

Acute hyperglycemia exacerbates myocardial ischemia/reperfusion injury and blunts cardioprotective effect of GIK
Su et al.
Am. J. Physiol. Endocrinol. Metab. 2007;293:E629-E635.
ABSTRACT | FULL TEXT  

Tight Blood Glucose Control With Insulin in the ICU: Facts and Controversies
Vanhorebeek et al.
Chest 2007;132:268-278.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies
Dirksen et al.
Cardiovasc Res 2007;74:343-355.
ABSTRACT | FULL TEXT  

Implications and Treatment of Acute Hyperglycemia in the Setting of Acute Myocardial Infarction
Zarich and Nesto
Circulation 2007;115:e436-e439.
FULL TEXT  

Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice
Hafstad et al.
Am. J. Physiol. Endocrinol. Metab. 2007;292:E1288-E1294.
ABSTRACT | FULL TEXT  

Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning
Schmidt et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;292:H1883-H1890.
ABSTRACT | FULL TEXT  

The Deleterious Effects of Hyperglycemia on Platelet Function in Diabetic Patients With Acute Coronary Syndromes: Mediation by Superoxide Production, Resolution With Intensive Insulin Administration
Worthley et al.
J Am Coll Cardiol 2007;49:304-310.
ABSTRACT | FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Standards of Medical Care in Diabetes--2007
American Diabetes Association
Diabetes Care 2007;30:S4-S41.
FULL TEXT  

Response to Letter Regarding Article, "Reperfusion Starts in the Ambulance"
Verheugt
Circulation 2006;114:e641-e641.
FULL TEXT  

Independent design and conduct of clinical trials
Yusuf and Bosch
Clin Trials 2006;3:503-507.
ABSTRACT  

Management of Hyperglycemia in the Hospital Setting
Inzucchi
NEJM 2006;355:1903-1911.
FULL TEXT  

Update in cardiology.
Rapaport
ANN INTERN MED 2006;145:618-625.
FULL TEXT  

Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance?
Ishihara et al.
Eur Heart J 2006;27:2413-2419.
ABSTRACT | FULL TEXT  

Is intensive insulin therapy safe in the critically ill?
Rady et al.
Chest 2006;130:1278-1281.
FULL TEXT  

Sudden cardiac death: the lost fatty acid hypothesis
Oliver
QJM 2006;99:701-709.
ABSTRACT | FULL TEXT  

Acute insulin resistance in myocardial ischemia: causes and consequences.
Smit and Romijn
SEMIN CARDIOTHORAC VASC ANESTH 2006;10:215-219.
ABSTRACT  

Glucose-insulin-potassium techniques in cardiac surgery: historical overview and future perspectives.
Van Wezel
SEMIN CARDIOTHORAC VASC ANESTH 2006;10:224-227.
ABSTRACT  

Glucose, insulin, and acute myocardial infarction
Das
Eur Heart J 2006;27:2141-2142.
FULL TEXT  

American College of Endocrinology and American Diabetes Association Consensus Statement on Inpatient Diabetes and Glycemic Control: A call to action
The ACE/ADA Task Force on Inpatient Diabetes
Diabetes Care 2006;29:1955-1962.
FULL TEXT  

Interaction of Insulin and AMPK in the Ischemic Heart: Another Chapter in the Book of Metabolic Therapy?
Tian and Balschi
Circ. Res. 2006;99:3-5.
FULL TEXT  

Fatty Acids Attenuate Insulin Regulation of 5'-AMP-Activated Protein Kinase and Insulin Cardioprotection After Ischemia
Folmes et al.
Circ. Res. 2006;99:61-68.
ABSTRACT | FULL TEXT  

Glucose metabolism and acute myocardial infarction
Vogelzang and Zijlstra
Eur Heart J 2006;27:1264-1265.
FULL TEXT  

Cardiovascular Disease
Bloomgarden
Diabetes Care 2006;29:1160-1166.
FULL TEXT  

Insulin protects cardiomyocytes against reoxygenation-induced hypercontracture by a survival pathway targeting SR Ca2+ storage
Abdallah et al.
Cardiovasc Res 2006;70:346-353.
ABSTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion in Patients With Acute Myocardial Infarction Without Signs of Heart Failure: The Glucose-Insulin-Potassium Study (GIPS)-II
Timmer et al.
J Am Coll Cardiol 2006;47:1730-1731.
FULL TEXT  

The Year in Interventional Cardiology
Dixon et al.
J Am Coll Cardiol 2006;47:1689-1706.
FULL TEXT  

Strict glucose control in the critically ill.
Watkinson et al.
BMJ 2006;332:865-866.
FULL TEXT  

Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
The OASIS-6 Trial Group*
JAMA 2006;295:1519-1530.
ABSTRACT | FULL TEXT  

The Hyperglycemia: Intensive Insulin Infusion In Infarction (HI-5) Study: A randomized controlled trial of insulin infusion therapy for myocardial infarction
Cheung et al.
Diabetes Care 2006;29:765-770.
ABSTRACT | FULL TEXT  

Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin.
Ellger et al.
Diabetes 2006;55:1096-1105.
ABSTRACT | FULL TEXT  

Insulin Therapy and In-Hospital Mortality in Critically Ill Patients: Systematic Review and Meta-analysis of Randomized Controlled Trials
Pittas et al.
JPEN J Parenter Enteral Nutr 2006;30:164-172.
ABSTRACT | FULL TEXT  

Glucose-Insulin and Potassium Infusions in Septic Shock
Hamdulay et al.
Chest 2006;129:800-804.
ABSTRACT | FULL TEXT  

Insulin Improves Myocardial Blood Flow in Patients With Type 2 Diabetes and Coronary Artery Disease
Lautamaki et al.
Diabetes 2006;55:511-516.
ABSTRACT | FULL TEXT  

Insulin: An overall cardiovascular protector?
Abdallah and Schafer
Cardiovasc Res 2006;69:4-6.
FULL TEXT  

Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation 2005;112:IV-89-IV-110.
FULL TEXT  

Role for insulin in acute myocardial infarction: ruled out or hard to prove?
van der Horst and Zijlstra
Eur Heart J 2005;26:2600-2600.
FULL TEXT  

Glycemic Control in the Intensive Care Unit: Why We Should Wait for NICE-SUGAR
Bellomo and Egi
Mayo Clin Proc. 2005;80:1546-1548.
 

The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
Collet and Montalescot
Diabetes and Vascular Disease Research 2005;2:136-143.
ABSTRACT  

Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA)
Meier et al.
Diabetes Care 2005;28:2551-2553.
FULL TEXT  

Percutaneous coronary intervention and beyond for ST-elevation acute myocardial infarction
Danzi et al.
Eur Heart J Suppl 2005;7:K26-K30.
ABSTRACT | FULL TEXT  

Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2005;10:126-126.
FULL TEXT  

Myocardial postconditioning: reperfusion injury revisited
Tsang et al.
Am. J. Physiol. Heart Circ. Physiol. 2005;289:H2-H7.
FULL TEXT  

Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction: Implications for Patients With and Without Recognized Diabetes
Kosiborod et al.
Circulation 2005;111:3078-3086.
ABSTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Apstein
JAMA 2005;293:2596-2597.
FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Cobb et al.
JAMA 2005;293:2597-2597.
FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial--Reply
Mehta et al.
JAMA 2005;293:2598-2598.
FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Dey et al.
JAMA 2005;293:2597-2598.
FULL TEXT  

A challenge to the metabolic approach to myocardial ischaemia
Apstein and Opie
Eur Heart J 2005;26:956-959.
ABSTRACT | FULL TEXT  

Is Glucose-Insulin-Potassium Therapy Beneficial in MI?
JWatch Emergency Med. 2005;2005:1-1.
FULL TEXT  

JournalScan
Malik
Heart 2005;91:559-560.
FULL TEXT  

Diabetes and Coronary Revascularization
Flaherty and Davidson
JAMA 2005;293:1501-1508.
ABSTRACT | FULL TEXT  

GIK Infusion Does Not Improve Post-STEMI Outcomes
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT